Results 271 to 280 of about 317,548 (356)

Optimized Reduced Field of View and Fat Suppression Methods for Interleaved Multislice In Vivo Cardiac Diffusion Tensor Imaging

Magnetic Resonance in Medicine, EarlyView.
ABSTRACT Purpose Slice interleaving, a limited phase encode (PE) field of view (FOV), and effective fat suppression are vital for efficient cardiac diffusion tensor imaging (cDTI) with minimal artifacts. This study aimed to optimize reduced FOV and fat suppression methods for interleaved multislice cDTI to improve signal‐to‐noise ratio (SNR) and ...
Yaqing Luo, Pedro F. Ferreira, Ke Wen, Ricardo Wage, Guang Yang, Dudley J. Pennell, Sonia Nielles‐Vallespin, Andrew D. Scott   +7 more
wiley   +1 more source

High Gene Expression Predicts Extremely Low Segregation of Deleterious Mutations in Large Penguin Populations. [PDF]

Mol Biol Evol
Trucchi E, Massa P, Giannelli F, Latrille T, Gargano M, Nitta Fernandes FA, Ancona L, Stenseth NC, Ferrer Obiol J, Paris J, Bertorelle G, Le Bohec C.   +11 more
europepmc   +1 more source

Omens of history : Su Tong\u27s southern landscape and dynastic histories = 歷史的凶兆 : 蘇童的南方景觀和朝代歷史

, 2011
LEE, Pui Yin, Vivian
core  

Evaluation of Third‐Order Motion‐Compensated Cardiac Diffusion Tensor Imaging Across Cardiac Phases Using an Ultra‐High‐Performance Clinical Scanner

Magnetic Resonance in Medicine, EarlyView.
ABSTRACT Purpose To evaluate a third‐order motion‐compensated spin echo (M3‐MCSE) sequence at multiple cardiac phases on a clinical 3 T MRI scanner with ultra‐high performance (UHP) gradients (200 mT/m), compared with stimulated echo acquisition mode (STEAM) and second‐order MCSE (M2‐MCSE) for cardiac diffusion tensor imaging (cDTI).
Ke Wen, Pedro F. Ferreira, Alberto Di Biase Oemick, Ricardo Wage, Karl P. Kunze, Fanwen Wang, Dudley J. Pennell, Andrew D. Scott, Sonia Nielles‐Vallespin   +8 more
wiley   +1 more source

Sodium-Glucose Cotransporter-2 Inhibitors Across the Glycemic Spectrum: Cardiovascular and Renal Outcomes With Mechanistic Insights. [PDF]

Cureus
Abdelfadil Elgazzar R, Ramadan M.
europepmc   +1 more source

Should We Consider Sacral Nerve Stimulation as a Treatment for Neurogenic Lower Urinary Tract Dysfunction? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims To explore the boundary of clinical use of sacral nerve stimulation (SNS) in neurogenic lower urinary tract dysfunction (NLUTD), identifying barriers to approval and early‐impact research questions. Methods This review is derived from a proposal discussion at the International Consultation on Incontinence‐Research Society in Bristol in ...
Marcus J. Drake, Mathijs de Rijk, Stefania Musco, Jalesh Panicker, Michał Późniak, Nikita Bhatt, Brigitte Schurch   +6 more
wiley   +1 more source

Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. [PDF]

Eur Heart J
Inker LA, Neuen BL, McCallum W, Vaduganathan M, Greene T, Heerspink HJL.   +5 more
europepmc   +1 more source

Omphalolith

JEADV Clinical Practice, EarlyView.
Mohammed Shanshal, Emily Moon
wiley   +1 more source

What Role Does the Central Nervous System Play in Refractory LUTS, and What Are the Therapeutic Implications? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims While many patients with lower urinary tract symptoms (LUTS) improve by treating peripheral causes, a substantial proportion continue to experience symptoms despite apparently successful interventions. Central nervous system (CNS) mechanisms could potentially contribute to persisting symptoms after the initial peripheral cause has been ...
Mathijs M. de Rijk, Michel Wyndaele, Ana Charrua, Christopher Fry, Paul Abrams, Gommert A. van Koeveringe, Anthony J. Kanai, Marcus J. Drake   +7 more
wiley   +1 more source

Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-Reduced. [PDF]

Eur J Heart Fail
Böhm M, Butler J, Abdin A, Filippatos G, Ferreira JP, Pocock SJ, Brueckmann M, Ofstad AP, Schueler E, Wanner C, Zannad F, Anker SD, Packer M, on behalf of the EMPEROR‐Reduced Trial Committees and Investigators.   +13 more
europepmc   +1 more source